Cargando…
IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model
The protocol used to induce cell death for generating vaccines from whole tumor cells is a critical consideration that impacts vaccine efficacy. Here we compared how different protocols used to induce cell death impacted protection provided by a prophylactic whole tumor cell vaccine in a mouse melan...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069009/ https://www.ncbi.nlm.nih.gov/pubmed/35529885 http://dx.doi.org/10.3389/fimmu.2022.884827 |
_version_ | 1784700344334286848 |
---|---|
author | Seaver, Kyle Kourko, Olena Gee, Katrina Greer, Peter A. Basta, Sameh |
author_facet | Seaver, Kyle Kourko, Olena Gee, Katrina Greer, Peter A. Basta, Sameh |
author_sort | Seaver, Kyle |
collection | PubMed |
description | The protocol used to induce cell death for generating vaccines from whole tumor cells is a critical consideration that impacts vaccine efficacy. Here we compared how different protocols used to induce cell death impacted protection provided by a prophylactic whole tumor cell vaccine in a mouse melanoma model. We found that melanoma cells exposed to γ-irradiation or lysis combined with UV-irradiation (LyUV) provided better protection against tumor challenge than lysis only or cells exposed to UV-irradiation. Furthermore, we found that the immunoregulatory cytokine, IL-27 enhanced protection against tumor growth in a dose-dependent manner when combined with either LyUV or γ-irradiated whole tumor cell vaccine preparations. Taken together, this data supports the use of LyUV as a potential protocol for developing whole tumor cell prophylactic cancer vaccines. We also showed that IL-27 can be used at low doses as a potent adjuvant in combination with LyUV or γ-irradiation treated cancer cells to improve the protection provided by a prophylactic cancer vaccine in a mouse melanoma model. |
format | Online Article Text |
id | pubmed-9069009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90690092022-05-05 IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model Seaver, Kyle Kourko, Olena Gee, Katrina Greer, Peter A. Basta, Sameh Front Immunol Immunology The protocol used to induce cell death for generating vaccines from whole tumor cells is a critical consideration that impacts vaccine efficacy. Here we compared how different protocols used to induce cell death impacted protection provided by a prophylactic whole tumor cell vaccine in a mouse melanoma model. We found that melanoma cells exposed to γ-irradiation or lysis combined with UV-irradiation (LyUV) provided better protection against tumor challenge than lysis only or cells exposed to UV-irradiation. Furthermore, we found that the immunoregulatory cytokine, IL-27 enhanced protection against tumor growth in a dose-dependent manner when combined with either LyUV or γ-irradiated whole tumor cell vaccine preparations. Taken together, this data supports the use of LyUV as a potential protocol for developing whole tumor cell prophylactic cancer vaccines. We also showed that IL-27 can be used at low doses as a potent adjuvant in combination with LyUV or γ-irradiation treated cancer cells to improve the protection provided by a prophylactic cancer vaccine in a mouse melanoma model. Frontiers Media S.A. 2022-04-21 /pmc/articles/PMC9069009/ /pubmed/35529885 http://dx.doi.org/10.3389/fimmu.2022.884827 Text en Copyright © 2022 Seaver, Kourko, Gee, Greer and Basta https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Seaver, Kyle Kourko, Olena Gee, Katrina Greer, Peter A. Basta, Sameh IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model |
title | IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model |
title_full | IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model |
title_fullStr | IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model |
title_full_unstemmed | IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model |
title_short | IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model |
title_sort | il-27 improves prophylactic protection provided by a dead tumor cell vaccine in a mouse melanoma model |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069009/ https://www.ncbi.nlm.nih.gov/pubmed/35529885 http://dx.doi.org/10.3389/fimmu.2022.884827 |
work_keys_str_mv | AT seaverkyle il27improvesprophylacticprotectionprovidedbyadeadtumorcellvaccineinamousemelanomamodel AT kourkoolena il27improvesprophylacticprotectionprovidedbyadeadtumorcellvaccineinamousemelanomamodel AT geekatrina il27improvesprophylacticprotectionprovidedbyadeadtumorcellvaccineinamousemelanomamodel AT greerpetera il27improvesprophylacticprotectionprovidedbyadeadtumorcellvaccineinamousemelanomamodel AT bastasameh il27improvesprophylacticprotectionprovidedbyadeadtumorcellvaccineinamousemelanomamodel |